Press Release

October 27th in Seattle: Groundbreaking Symposium on Psychedelics & End-of-Life Care

Leaders in Palliative Care, Psychedelic Research and Drug Law Reform to Present at Psychedelic Medicine: New Frontiers in Palliative Care

Speakers Include Rick Doblin, Ethan Nadelmann and Kathryn Tucker, As Well As Elected Officials, Doctors, Scientists, Attorneys and Ethicists

Jag Davies, 212-613-8035

Exciting new research is revealing that psychedelic drugs, such as psilocybin, LSD and MDMA may offer significant benefit for patients struggling at the end of life and those beset by major depression and treatment-resistant post-traumatic stress.

On Friday, October 27 a first-of-its-kind symposium will be held at the University of Washington School of Law, bringing together doctors, scientific researchers, attorneys and ethicists. The speakers will consider the medical, legal and ethical implications of emerging research on psychedelics and end-of-life care. They will also center the discussion around the shifting policies and priorities of our state and federal drug laws.

This symposium is co-organized by the Drug Policy Alliance, the End of Life Liberty Project, and the Center for Law, Science and Global Health at the University of Washington School of Law.

Speakers include MAPS Executive Director Rick Doblin, End of Life Liberty Project Executive Director Kathryn Tucker, former DPA Executive Director Ethan Nadelmann, professor and author Ingrid Walker, Washington State Representative Roger Goodman, and many more.

Psychedelic Medicine: New Frontiers in Palliative Care
When: Friday, October 27, 8am – 5pm
Where: University of Washington School of Law, William H. Gates Hall, Seattle

The symposium's agenda includes the following panels and presentations:

  • Overview of Developments in Law and Medicine Governing End of Life Care
  • Panel Discussion with End of Life Care Providers: How has patient care decision-making changed as a result of the movement for “Death with Dignity”? Who has benefitted and who has been left behind?
  • History of Psychedelic Substances in Medicine
  • What’s the Latest Psychedelic Research Telling Us?
  • Lunchtime Talks by Ethan Nadelmann and Kenneth Tupper
  • Regulatory Pathways to Patient Access
  • The Medicinal Marijuana Experience: Legal, Political and Advocacy Parallels for Medicinal Psychedelics
  • Pathways Forward: Legal, Social and Ethical Challenges and Opportunities

Those planning to attend the symposium are encouraged to register immediately, as space is limited.